Purpose To further our understanding of the relationships between asthma control and health-related quality of life (HRQOL) and provide insights into the relative usefulness of various measures in different research contexts. We present a conceptual model and test it with longitudinal survey data. Methods Participants recruited via population sampling and hospital Emergency Departments completed questionnaires every 6 months for up to 3 years. Measures included: sleep disturbance, use of short-acting beta agonists (SABA), activity limitation, urgent medical visits, hospital use, Marks' Asthma Quality of Life Questionnaire (AQLQ-M) and the SF-36 Health Survey. Correlation analysis and multi-level models tested predictions from the conceptual model. Results A total of 213 people with asthma aged 16-75 years provided 967 observations. Correlations between asthma control and asthma-specific HRQOL were stronger than those between asthma control and generic HRQOL. The asthma control variables explained 54-58% of the variance in asthmaspecific HRQOL and 8-25% of the variance in generic HRQOL. Activity limitation was the main contributor to between-person variation, while sleep disturbance and SABA use were the main contributors to within-person variation.
Introduction
The impact of asthma on health-related quality of life (HRQOL) is influenced by the severity of the disease and the degree to which it is controlled. While asthma severity is not directly measurable, it can be inferred from the amount and type of treatment required to maintain asthma control and the observed level of control [1] [2] [3] . Observable indicators of asthma control include the frequency and severity of day-time and night-time symptoms, the extent of activity limitation due to asthma, the level of lung function and the frequency with which short-acting bronchodilator (or 'reliever') medication is required [4] [5] [6] . Similarly, HRQOL is not directly measurable, but can be inferred from the self-report of symptoms and their impact on patients' ability to function physically, socially and emotionally. A number of HRQOL questionnaires are available; some measure the specific impact of asthma (disease-specific instruments), while others address the impact of health impairment generally (generic instruments) [7, 8] .
There is some evidence about the relationship between HRQOL and asthma control. Vollmer et al. [9] found that perceived asthma control, activity limitation due to asthma, night waking due to asthma and overuse of reliever medication were all correlated with asthma-specific HRQOL, and all except reliever overuse correlated with generic HRQOL. Katz et al. found that the number of life activities affected by asthma and the individual's perceived control of asthma explained variations in asthma-specific HRQOL, cross-sectionally and longitudinally [10, 11] . Chen et al. [12] found that the number of asthma control problems at baseline was a significant predictor of asthma-specific and generic HRQOL 12 months later, after adjusting for other covariates at baseline (lung function, severity, demographic characteristics and co-morbidity). Change in control from baseline to 12 months was also a significant predictor of asthma-specific but not generic HRQOL, after adjusting for baseline control [12] . However, the relationship is complex. There is evidence that the relation between asthma control and HRQOL is altered by effective treatment [13] . Further, factor analysis on questions from commonly used measures of severity, control and HRQOL suggests that these questionnaires measure separate but related domains for generic HRQOL, asthma-specific HRQOL and asthma control, but do not clearly identify discrete domains for control and severity [5] .
The aim of this paper is to generate hypotheses from a conceptual model of the relationships between various aspects of asthma control and HRQOL, to test them in a cohort with asthma of varying severity and to discuss the implications in terms of which constructs might provide the best outcome measures for monitoring the effect of treatment and for evaluating new interventions.
Conceptual model
Asthma control and HRQOL are part of a dynamic system involving the individual, their environment and their treatment (Fig. 1) . Innate asthma severity is likely to remain relatively stable or change only mildly over a person's life-time [14] . Environmental factors, such as exposure to viral infections [15] , allergens [16] or both [17] , may cause acute exacerbations or periods of poor asthma control. Treatment aims to ameliorate the manifestations of both the chronic state and acute exacerbations. The degree to which treatment is effective determines the level of asthma control, which, in turn, determines the amount of treatment required. When this feedback system works well, it minimises the frequency and intensity of symptoms and titrates the medication requirement to the appropriate level. When asthma is well controlled, asthma symptoms are maintained at the lowest levels possible and the impact of asthma on HRQOL is minimised. Poor function of the feedback system equates to poor disease management, which results in the poor control of asthma and/or over-or under-treatment. These effects flow on to physical, emotional and social functioning. Because an individual's experience of illness and perception of its impact is subjective, the self-report of symptoms and HRQOL is influenced by personality traits and the ability to adapt and cope [18] . Other factors such as co-morbidities and life events also influence quality of life and, hence, dilute the relative impact of asthma on generic HRQOL.
This conceptual model suggests a series of a priori expectations:
-Asthma control should have a more direct impact on asthma-specific HRQOL measures than on generic measures. Thus, we expect correlations between asthma control and asthma-specific HRQOL to be stronger than correlations between asthma control and generic HRQOL. -Similarly, we expect asthma-specific HRQOL measures to be more sensitive than generic measures to changes in asthma control. Thus, correlations between change in asthma control and change in asthma-specific HRQOL should be stronger than correlations between change in asthma control and change in generic HRQOL. -While we expect asthma treatment will have a beneficial effect on asthma control and asthma-specific HRQOL, we also expect that the measured benefit in an observational cohort study will be attenuated or possibly Fig. 1 Expected relationship between asthma and health-related quality of life (HRQOL) reversed by the feedback effect of control and HRQOL on treatment. Since it is unclear what the sum of these counter-expectations is, we expect these associations to be weak and their direction unpredictable. -Enduring features of individuals, such as innate asthma severity and personality traits, will lead to differences among individuals in asthma-specific and generic HRQOL that persist over time. Thus, we expect that variations in longitudinal HRQOL data will be dominated by differences between individuals in their average levels of HRQOL (between-person variance) rather than fluctuations in an individual's experience over time around their own average levels of HRQOL (within-person variance). -We expect that individual characteristics, such as age and gender, will explain some of the between-person variance in HRQOL. -We expect that asthma control variables will explain a significant amount of within-person variance in HRQOL and some between-person variance.
Methods

Recruitment and sample
Subjects were participating in a longitudinal study of the economic burden of asthma in New South Wales (NSW), Australia, which commenced in 2002 [19] . The study used two sampling frames: (1) a random community sample stratified by age, gender and area of residence (22% response); and (2) the Emergency Department databases at three tertiary hospitals (9% response [20] , which contains 20 items covering social activity limitations, mood and some practical and existential concerns. We used the total scale as a comprehensive measure of asthma-specific HRQOL and the five-item breathing problems sub-scale as a measure of troublesome asthmarelated symptoms. These scales have a range of 0-4; higher scores reflect greater impact of asthma. Generic HRQOL was measured with the Physical Component Summary (PCS) and Mental Component Summary (MCS) scales from the SF-36 Health Survey version 1 [21] . These were calculated as per the user manual [22] using Australian population norms and scoring weights [23] . These scales are normalised to a population mean of 50 and standard deviation of 10; higher scores reflect better HRQOL.
Statistical analysis
Statistical analyses were performed with SAS software version 9.1 [24] . The relative size of associations between asthma control and disease-specific versus generic HRQOL were tested with Spearman correlation coefficients among baseline measures. Spearman correlation coefficients were also used to determine the association between change in HRQOL and change in asthma control. The prediction from the conceptual model was that this association would be stronger for asthma-specific than for generic HRQOL measures, and that this would demonstrate that the former were more sensitive to change in control than the latter. For this analysis, change scores were calculated as follows. The two time-points when each individual's SABA use was at the minimum and maximum levels were identified. Change scores were calculated for all measures of asthma control and HRQOL as the difference between those two timepoints. SABA use was chosen because it had a relatively even distribution across its range and, therefore, yielded a larger range of change scores than the other control measures, which were more skewed. Each individual's maximum change score for each control and HRQOL measure was also calculated. The significance of differences between correlation coefficients was assessed by the comparison of their 95% confidence intervals [25] , although we note that this is only an approximate test of statistical significance because the assumption of independence of the correlation coefficients does not hold in this context. Multi-level models [26] , estimated in SAS Proc Mixed [24] , were used to examine HRQOL patterns over time [27] ; specifically, the relative size of within-and between-person variation, the explanatory power of asthma control and personal characteristics, and whether the relationships between asthma control and HRQOL varied among individuals. Measurement occasion (level 1) was nested within individuals (level 2), HRQOL was the outcome variable and explanatory variables included asthma control, socio-demographic variables (age, gender, area of residence), recruitment source and smoking status. Excepting hospital use, each asthma control variable was centred on its overall mean.
Each of the four HRQOL scales was analysed separately, with the following steps and models:
Step 1 One model with a person-specific random intercept (no explanatory variables);
Step 2 One model with a random intercept plus five explanatory variables (included simultaneously): age, gender, residential area (capital city or regional NSW), smoking status (current smoker or not), recruitment source (community or hospital), entered as level 2 (person level) effects;
Step 3 Five models, each containing only one asthma control variable (with one corresponding fixed parameter), added to the model at Step 2 as level 1 (time-varying) effects;
Step 4 Five models, corresponding to the five models at
Step 3 plus a person-specific random slope parameter for the corresponding asthma control variable (the likelihood ratio test was used to determine if the addition of the random slope parameter improved the model fit for each control variable separately); Step 5 One model, being the model from Step 2 with all five of the asthma control variables included simultaneously as fixed effects (i.e. five fixed parameters), plus a random slope parameter for a control variable only where this was indicated by the models at Step 4 (the likelihood ratio test was The appendix gives the detailed specification of all these statistical models.
The proportion of total variance due to between-person variance was calculated from estimates of between-and within-person variance in Step 1 above [26, p. 19] . The proportion of between-and within-person variance explained by asthma control and personal variables was calculated from corresponding variance estimates in the models at Steps 4 and 5 relative to Step 1 above [28] .
Results
The sample comprised 213 people with asthma aged 16 to 75 years who completed one or more HRQOL assessments during the study (Table 2) . At baseline, the majority reported few problems with asthma control. However, some individuals showed evidence of poor asthma control, with 15% reporting an asthma attack requiring a medical visit in the previous 4 weeks, 15% reporting hospital use in the previous 6 months and some high scores on all asthma control measures. The baseline AQLQ-M mean scores were close to 1, representing a mild effect of asthma on HRQOL on average, with some individuals experiencing moderate to very severe effects. The baseline mean SF-36 summary scales were about 5 points below the population mean of 50, with a wide range of scores reflecting considerable variation in physical and mental health among individuals. The absolute maximum changes in asthma control and HRQOL were relatively small in general, although some individuals experienced moderate to large changes in control and HRQOL. The 213 participants contributed a total of 967 observations, with a maximum follow-up of 3 years. Attrition of approximately 10% occurred at each of the six assessments. In total, 124 (58%) respondents completed all scheduled surveys. Compared with these subjects, the 89 subjects who missed at least one survey were younger (mean age at recruitment: 39 vs. 49 years, P \ 0.0001) and had more sleep disturbance (on average 1.3 nights/week in the last 4 weeks versus 0.9, P = 0.006).
At baseline, the five asthma control variables were more highly correlated with the asthma-specific HRQOL measures (AQLQ-M) than with the generic measures (SF-36), and about half of these correlations were significantly higher (Table 3) . Change in sleep disturbance, SABA use and activity limitation were more highly correlated with change in the asthma-specific HRQOL measures than with change in the generic measures, and about half of these correlations were significantly higher. Change in urgent medical visits and hospital use were not highly correlated with change in any of the HRQOL measures (r = 0.02-0.24, Table 3 ).
Most of the variability in the longitudinal HRQOL data was due to between-rather than within-person differences (Table 4) . When the asthma control variables were individually entered into the multi-level models of AQLQ-M total, AQLQ-M breathing and PCS, the best fit was achieved with a random slope for all asthma control variables except hospital use. This indicated significant variation among individuals in the rate at which HRQOL changed with these control variables. Not all control variables retained significant random slopes when the five asthma control variables were entered together. The effect of treatment was not significant and explained no additional variance in any of the four HRQOL scales. The final models are presented in Table 4 .
Socio-demographic factors, smoking status, recruitment source and the asthma control variables together explained more than 70% of the total variance in the asthma-specific HRQOL scales, 50% in the PCS but only 16% in the MCS. Most of the variation in asthma-specific HRQOL was attributable to the asthma control variables, which, together, explained 54-58% of the total variance and more than half of the between-and within-person variation (Fig. 2) . This was not the case for generic HRQOL, where sociodemographic characteristics, smoking status and recruitment source accounted for much of the explainable variation between people. The asthma control variables together explained 25% of the total variance in the PCS, less than 20% of the within-person variation and almost 30% of the between-person variation (Fig. 2) . The asthma control variables explained only 8% of the total variance in the MCS.
Activity limitations, SABA use and sleep disturbance contributed the most toward explaining variation between people in the AQLQ-M breathing scores, individually accounting for 30-50% of between-person variance (Fig. 3) . Sleep disturbance and SABA use contributed the most toward explaining the fluctuations that individuals experienced over time, each individually accounting for about 40% of the within-person variance in the AQLQ-M breathing scores (Fig. 3) . The pattern was similar for the AQLQ-M total scores (Fig. 4) , except that the proportion a Spearman rank correlations. The correlations for the SF-36 scales are negative because, on these scales, a higher score reflects better HRQOL, while on the AQLQ-M scales, a higher score reflects greater impact of asthma (worse HRQOL), and for all of the asthma control measures, a higher score reflects worse control. Confidence intervals ranged from ?/-0.08 to ?/-0.14, with larger correlation coefficients having smaller confidence intervals b Change scores based on the two time-points when each individual's SABA use was at the minimum and maximum levels c Hospital use = any hospital admission or Emergency Department attendance for asthma of the variance explained was slightly smaller. A similar pattern was also seen for the PCS, with a much smaller proportion of the variance explained (Fig. 5) . It is similar for the MCS, but with an even smaller proportion of variance explained. Two of our measures of asthma control (hospital use and urgent medical visits) showed very little variation (0 at all time-points for more than 70% of the sample) and, so, explained very little between-or withinperson variation in any of the HRQOL scales.
Discussion
These findings generally support the hypotheses arising from our conceptual model. The observed correlations and the results from the multi-level models support the propositions that asthma control has a more direct impact on asthma-specific HRQOL measures than on generic measures, and that asthma-specific measures of HRQOL are more sensitive than generic measures to changes in asthma control. This is consistent with previous evidence that disease-specific HRQOL measures are more responsive to changes in HRQOL than are generic HRQOL measures [29] . The asthma control variables explained very little of the variation in mental aspects of generic HRQOL, more of the variation in physical aspects of generic HRQOL and over half of the variance in asthma-specific HRQOL, both between and within individuals. Activity limitations, sleep disturbance and SABA use were the main contributors to this. It is perhaps not surprising that urgent medical visits and hospital use had the least explanatory power, given that they had the least variability of the control measures in our data. Further, they are arguably byproducts rather than dimensions of poor control. We had expected an unpredictable and probably weak association between treatment and HRQOL in this cohort because of the feedback loop between asthma control and treatment intensity. The finding that, after adjusting for asthma control and socio-demographic factors, the reported use of inhaled corticosteroids or combined therapy was not related to HRQOL is consistent with this prediction.
Our findings are consistent with several other reports on the relation between measures of asthma control and HRQOL. In Katz et al.'s cohort, activity limitation due to asthma explained 32% of the variance in asthma-specific HRQOL (measured with Marks' AQLQ-M) at baseline and 20% in change over 18 months [11] . In the same cohort, perceived control of asthma explained 15% of the variance in asthma-specific HRQOL at baseline and 15% in change over 3 years, while it explained less than 10% of the variance in generic HRQOL (measured with the SF-36) [10] . Chen et al. [12] found that the number of asthma control problems at baseline and change one year later explained 27% of the variance in asthma-specific HRQOL (Juniper's AQLQ) and 7% of the variance in generic HRQOL (Euroqol-5D). Vollmer et al. [9] found that the report of normal activities missed due to asthma was a significant predictor of both asthma-specific and generic HRQOL (measured with Juniper's AQLQ and the SF-36, respectively). However, unlike our study, Vollmer et al. [9] found that reliever overuse was not associated with the SF-36 PCS. Moy et al. found that SABA use predicted asthma-specific HRQOL (measured with Juniper's AQLQ) in patients with mild asthma but not in patients with moderate to severe asthma [13] . We have added a further dimension to the evidence from these studies by using multi-level models to show that the relationship between asthma control and HRQOL varies significantly among individuals. Historically, asthma-specific HRQOL instruments such as Juniper's AQLQ and Marks' AQLQ-M were developed before measures of control, which emerged as the focus of health care shifted to asthma management and control, as reflected in initiatives such as the Global Initiative for Asthma [30] . Our study was designed before these measures emerged. Contemporary measurement of control includes objective measures (i.e. pulmonary function tests) and subjective measures (i.e. symptoms, quality of life) [31] . Asthma symptoms and activity limitation are included in most measures of asthma control and HRQOL. The resultant overlap is an obvious source of the correlation between measures of control and HRQOL observed in this and other studies [5, [9] [10] [11] [12] [13] . It is worth considering the extent to which our and others' results merely reflect this overlap, as opposed to more interactive relationships. In our study, the greatest overlap was between asthmaspecific HRQOL and our survey's additional measure of activity limitation (Table 1 ). In the AQLQ-M, eight of the 20 questions relate more or less directly to limitations due to asthma in various aspects of life. This no doubt explains why these two measures were so strongly correlated in our data (Table 3) . Further, the longer timeframe for our activity limitation measure ('the last 6 months') may account for it explaining more of the between-person variance than the within-person variance in the AQLQ-M scores (based on 'the last 4 weeks'). The AQLQ-M also contains a question about sleep ('unable to sleep at night'), but as it is only one of 20 items in the total AQLQ-M score, it is unlikely to have had much influence on the degree of correlation with our control measure (number of nights sleep disturbed). The results for the control measure based on the use of SABA were not affected at all by the overlap of content with HRQOL. It is noteworthy that the correlations for this control variable were comparable with those of the sleep control variable (Table 3) .
Identifying the aspects of asthma control that explain variations in HRQOL may assist in targeting interventions to improve HRQOL. For example, interventions aimed at reducing sleep disturbance in asthma may be worth pursuing. Understanding these relationships may also inform the choice of endpoints for clinical trials. If measures of asthma control are more efficient for detecting treatment effects than HRQOL measures (i.e. more responsive), and are known to be correlated with them, then it would make sense to use measures of control as endpoints, even when the ultimate goal of treatment is to optimise HRQOL. This is a useful direction for further investigation under standardised conditions where systematic treatment effects are expected and measures of both asthma control and HRQOL have been used.
Our study has some potential limitations. Our recruitment strategy and low response rates mean that we may not have captured a representative sample of people with asthma in NSW. However, it is unlikely that the factors associated with non-response influenced the relationships between control and HRQOL. Sample attrition occurred, but we found few differences between those who completed all assessment points and those who did not. We did not measure all of the aspects of asthma treatment and impact in our theoretical model. In particular, we did not measure all indicators of asthma control, such as day-time symptoms and the level of lung function. Furthermore, we did not use a composite measure of asthma control; Bateman et al. [32] found that, in patients with uncontrolled asthma, individual measures of asthma control varied in their speed of response to treatment and the proportion achieving control on individual measures was higher than on all measures, suggesting that the use of individual measures may overestimate control. The conceptual model and empirical results presented here provide some practical insights into the relationships between measures of HRQOL and asthma control, and their usefulness in different research contexts. The measures of asthma control used in this and other studies are often single items that have clear clinical interpretations and relevance. This makes them much easier to interpret than multi-item HRQOL measures [33] . So, while the ultimate aim of asthma management is to optimise HRQOL, it may be more practical in some circumstances to measure asthma control. The finding that sleep disturbance due to asthma and SABA use explains much of the within-person variation in asthma-specific HRQOL suggests that these particular measures of asthma control are likely to be the most useful in evaluating treatment effectiveness. Since activity limitation explains much of the between-person variation in HRQOL that is not explained by personal characteristics, it may be a better measure of asthma control when monitoring the impact of asthma in populations.
Each of the four HRQOL scales was analysed, separately, in the following sequence and with the following models:
Step 1 One model: a random intercept model
for i = 1 to n participants on j = 1 to 6 occasions (the 6 9 6-monthly timepoints of the 3-year survey period), where y ij is the QOL score for patient i on the jth occasion, a is the population mean QOL score (intercept), u i is a random effect giving the deviation of the average QOL score of the ith patient from the population mean, and e ij gives the deviation of y ij from the average QOL score of the ith patient.
In this model and all subsequent models, u i and e ij are assumed to be independent and normally distributed, with mean zero, between-patient variance r 2 u and within-patient variance is r 2 e . Thus; u i $ Nð0; U 2 u Þ; e ij $ Nð0; U 2 e Þ The covariance matrix for the e ij was modelled as unstructured (no constraints) at this stage.
Step 2 One model: five explanatory variables were added simultaneously to the model at Step 1; age, gender, residential area (capital city or regional NSW), smoking status (current smoker or not), recruitment source (community or hospital):
where x ki are the observed levels of k = 1 to 5 recruitment and socio-demographic variables for the ith participant. These variables are called 'person level' or 'level 2' effects, and there is only one value of x ki for each participant, as measured at baseline. b k is the regression parameter (slope) for the kth socio-demographic variable.
Step 3 Five models, each containing only one asthma control variables (with one corresponding fixed parameter), added to the model at Step 2 as level 1 (time varying) effects:
where z ijl is the observed level of the lth asthma control variable for participant i at time j. These variables are called 'time varying' or 'level 1' effects, and there was one value of z ijl each time each participant completed a survey. Each asthma control variable was centred on its overall mean, except hospital use. c l is the regression parameter (a fixed slope parameter) for the lth asthma control variable.
Step 3 plus a person-specific random slope parameter for the corresponding asthma control variable;
where v il is a subject-specific effect giving the deviation of the ith subject-specific slope from the population slope, c l , for the lth asthma control variable. v il were assumed to be normally distributed, with mean zero, v il $ Nð0; U 2 v Þ, and to be independent of u i and e ij . The likelihood ratio test was used to compare each model with the corresponding model at Step 3 to determine whether the random slope improved model fit.
Step 5 One model, being the model from Step 2 with all five of the asthma control variables, included simultaneously as fixed effects (i.e. five fixed parameters), plus a random slope parameter for a control variable only where this was indicated by the models at 4:
where v 1i ,…,v Li were retained if they improved the model fit. The covariance matrix for e ij was constrained to a variance components structure (zeros in the off-diagonals) at this stage because the large number of random effects lead to convergence problems with other covariance structures. The likelihood ratio test was used again at Step 5 to determine if all random slopes retained in the five separate models at Step 4 continued to contribute to the single model at Step 5; the model of best fit here was then the final model from Step 5;
Step 6 One model, being the final model from Step 5 plus two dummy variables for treatment (level 1 effects): (1) ICSLABA, indicating regular users of combined ICS and LABA; (2) ICS, indicating regular users of ICS alone:
Since neither treatment effect was statistically significant for any of the four HRQOL scales, the final model was the best fit model from Step 5.
